RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Clinical trials for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat nose and throat cancer: four experimental combos tested
Disease control Recruiting nowThis study tests four different drug combinations in 208 adults with advanced nasopharyngeal cancer that has stopped responding to standard treatments, including PD-1 inhibitors. The goal is to see which combination best shrinks tumors and controls the disease. Participants will …
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated May 26, 2026 10:05 UTC
-
New hope for advanced nose cancer? drug combo trial begins
Disease control Recruiting nowThis study tests a new drug (YL201) combined with an immunotherapy (toripalimab), with or without chemotherapy (cisplatin), in people whose nasopharyngeal cancer has come back or spread. The goal is to see if the combination is safe and helps control the cancer. About 202 adults …
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 09:35 UTC
-
New drug cocktail aims to shrink Hard-to-Treat head and neck cancers
Disease control Recruiting nowThis study tests a combination of three drugs (sintilimab, anlotinib, and a taxane chemotherapy) in 33 adults with nasopharyngeal cancer that has returned or spread and hasn't responded to prior treatments. The goal is to see if this combo can shrink tumors and control the diseas…
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for hard-to-treat nose and throat cancer?
Disease control Recruiting nowThis study tests whether a new combination of two drugs (MRG003 and pucotenlimab) works better than standard chemotherapy for people whose nasopharyngeal cancer has come back or spread. About 446 adults who have already tried at least one other treatment will take part. The goal …
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Miracogen Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC